淋巴瘤治疗后继发急性白血病研究进展  

Research progress of secondary acute leukemia after treatment of lymphoma

作　　者：余庭玉 王利[1] YU Tingyu;WANG Li

机构地区：[1]重庆医科大学附属第一医院血液科,重庆400010

出　　处：《临床血液学杂志》2020年第5期664-669,共6页Journal of Clinical Hematology

基　　金：重庆市科卫联合医学科研项目重点项目(No:2018ZDXM001)。

摘　　要：淋巴瘤是起源于淋巴结和淋巴组织的免疫系统恶性肿瘤,按组织病理学改变,可分为霍奇金淋巴瘤(Hodgkin lymphoma,HL)和非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)。治疗相关性白血病(therapy-related leukemia,TRL),也被称为继发性白血病,是指原患肿瘤或非肿瘤性疾病者接受化疗和(或)放疗后若干年而发生的急性白血病。近年来,医疗水平的不断提高使得淋巴瘤的预后得到了很大的改善。Therapy-related leukemia,also known as secondary leukemia,refers to acute leukemia that occurs several years after chemotherapy and/or radiotherapy in patients with a primary tumor or non-tumor disease.This article reviews the risk factors,pathogenesis,prognosis and treatment progress of secondary acute leukemia after lymphoma treatment.

关 键 词：淋巴瘤 治疗相关性白血病 危险因素 发病机制 

分 类 号：R733.4[医药卫生—肿瘤]